Abstract
AbstractWith the growing availability of Alzheimer’s disease (AD) transcriptomic data, several studies have nominated new therapeutic targets. However, a major challenge is accounting for latent (hidden) factors which affect the discovery of therapeutic targets. Using unsupervised machine learning, we identified a latent factor in brain tissue, and we validated the factor in AD and normal samples, across multiple studies, and different brain tissues. Moreover, significant metabolic differences were observed due to the latent factor. The latent factor was found to reflect cell-type heterogeneity in the brain and after adjusting for it, we were able to identify new biological pathways. The changes observed at both transcriptomic and metabolomic levels support the importance of identifying any latent factors before pursuing downstream analysis to accurately identify biomarkers.
Publisher
Cold Spring Harbor Laboratory